A recent study from Japan has outlined a new PET scoring system for predicting whether prostate cancer patients will respond to treatment with investigational therapy Lu-PSMA-617.
"Identification of patients who will likely benefit from PSMA-targeted radiopharmaceutical therapy remains an unmet clinical need," said first author Dr. Masatoshi Hotta, PhD, in a news release from the Society for Nuclear Medicine and Molecular Imaging (SNMMI). The study was published on 30 March in the Journal of Nuclear Medicine.
In the study, the researchers created a quantitative PSMA-PET tumor-to-salivary gland ratio (qPSG) score based on imaging in 237 men. They then interpreted the scans and assigned a visual PSG score (vPSG) based on the data. When they tested the scores in patients receiving Lu-PSMA-617, patients with high qPSG and vPSG scores had longer progression-free survival and longer overall survival, according to the findings.
Ultimately, the findings could be valuable in advancing precision medicine in the emerging field of theranostics, the researchers said.